Nasal Epithelium Transcriptomics Predict Clinical Response to Elexacaftor/Tezacaftor/Ivacaftor
American Journal of Respiratory Cell and Molecular Biology · 01.12.2024 · 71 (6) · 730-739
DOI: 10.1165/rcmb.2024-0103oc ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Respiratory Cell and Molecular Biology, online erschienen am 01.12.2024. Verfasst von Molin Yue und 10 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Pulmonary Medicine, University of Pittsburgh Medical Center Children's Hospital of Pittsburgh, and. Hauptthemen laut MEDLINE: Aminophenols, Nasal Mucosa, Cystic Fibrosis, Indoles. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NICHD NIH HHS, NHLBI NIH HHS, Department of Pediatrics at the University of Pittsburgh.
Abstract (Originalsprache)
Elexacaftor/tezacaftor/ivacaftor (ETI) has had a substantial positive impact for people living with cystic fibrosis (pwCF). However, there can be substantial variability in efficacy, and we lack adequate biomarkers to predict individual response. We thus aimed to identify transcriptomic profiles in nasal respiratory epithelium that predict clinical response to ETI treatment. We obtained nasal epithelial samples from pwCF before ETI initiation and performed a transcriptome-wide analysis of baseline gene expression to predict changes in forced expiratory volume in 1 second (ΔFEV1), year’s best FEV1 (ΔybFEV1), and body mass index (ΔBMI). Using the top differentially expressed genes, we generated transcriptomic risk scores (TRSs) and evaluated their predictive performance. The study included 40 pwCF ≥6 years of age (mean, 27.7 [SD, 15.1] years; 40% female). After ETI initiation, FEV1 improved by ≥5% in 22 (61.1%) participants, and ybFEV1 improved by ≥5% in 19 (50%). TRSs were constructed using top overexpressed and underexpressed genes for each outcome. Adding the ΔFEV1 TRS to a model with age, sex, and baseline FEV1 increased the area under the receiver operating characteristic curve (AUC) from 0.41 to 0.88, the ΔybFEV1 TRS increased the AUC from 0.51 to 0.88, and the ΔBMI TRS increased the AUC from 0.46 to 0.92. Average accuracy was thus ∼85% in predicting the response to the three outcomes. Results were similar in models further adjusted for F508del zygosity and previous CFTR modulator use. In conclusion, we identified nasal epithelial transcriptomic profiles that help accurately predict changes in FEV1 and BMI with ETI treatment. These novel TRSs could serve as predictive biomarkers for clinical response to modulator treatment in pwCF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pediatric Pulmonary Medicine, University of Pittsburgh Medical Center Children's Hospital of Pittsburgh, and.
- Cystic Fibrosis Center, University of Pittsburgh, Pittsburgh, Pennsylvania; and.
- Pediatric Pulmonology, Allergy, and Sleep Medicine, School of Medicine and Riley Hospital for Children, Indiana University, Indianapolis, Indiana.
ORCID-Profile: Daniel J Weiner, Franziska J Rosser, Juan C Celedón, Wei Chen, Erick Forno
Förderung
- NICHD NIH HHS
- NHLBI NIH HHS
- Department of Pediatrics at the University of Pittsburgh
- National Heart, Lung, and Blood Institute
Zitieren
APA
Yue, M., Weiner, D. J., Gaietto, K. M., Rosser, F. J., Qoyawayma, C. M., Manni, M. L., Myerburg, M. M., Pilewski, J. M., Celedón, J. C., Chen, W., & Forno, E. (2024). Nasal Epithelium Transcriptomics Predict Clinical Response to Elexacaftor/Tezacaftor/Ivacaftor. American Journal of Respiratory Cell and Molecular Biology, 71(6), 730-739. https://doi.org/10.1165/rcmb.2024-0103oc
Vancouver
Yue M, Weiner DJ, Gaietto KM, Rosser FJ, Qoyawayma CM, Manni ML, et al. Nasal Epithelium Transcriptomics Predict Clinical Response to Elexacaftor/Tezacaftor/Ivacaftor. American Journal of Respiratory Cell and Molecular Biology. 2024;71(6):730-739. doi:10.1165/rcmb.2024-0103oc
BibTeX
@article{Yue2024,
author = {Yue, Molin and Weiner, Daniel J and Gaietto, Kristina M and Rosser, Franziska J and Qoyawayma, Christopher M and Manni, Michelle L and Myerburg, Michael M and Pilewski, Joseph M and Celedón, Juan C and Chen, Wei and Forno, Erick},
title = {Nasal Epithelium Transcriptomics Predict Clinical Response to Elexacaftor/Tezacaftor/Ivacaftor},
journal = {American Journal of Respiratory Cell and Molecular Biology},
year = {2024},
volume = {71},
number = {6},
pages = {730--739},
doi = {10.1165/rcmb.2024-0103oc}
}
EUVIMED